Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine.

× No keyword cloud information.

29 in total

1. Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.

Authors: Li-Fang Yu; Werner Tückmantel; J Brek Eaton; Barbara Caldarone; Allison Fedolak; Taleen Hanania; Dani Brunner; Ronald J Lukas; Alan P Kozikowski
Journal: J Med Chem Date: 2012-01-04 Impact factor: 7.446

2. Hippocampal α7 nicotinic ACh receptors contribute to modulation of depression-like behaviour in C57BL/6J mice.

Authors: Yann S Mineur; Tenna N Mose; Sam Blakeman; Marina R Picciotto
Journal: Br J Pharmacol Date: 2017-04-08 Impact factor: 8.739

Review 3. Neurobiological substrates of Tourette's disorder.

Authors: James F Leckman; Michael H Bloch; Megan E Smith; Daouia Larabi; Michelle Hampson
Journal: J Child Adolesc Psychopharmacol Date: 2010-08 Impact factor: 2.576

Review 4. Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature.

Authors: Noah S Philip; Linda L Carpenter; Audrey R Tyrka; Lawrence H Price
Journal: Psychopharmacology (Berl) Date: 2010-07-08 Impact factor: 4.530

Review 5. Examining antidepressant drug response by smoking status: why is it important and how often is it done?

Authors: Andrea H Weinberger; Sherry A McKee; Marina R Picciotto; Carolyn M Mazure
Journal: J Psychopharmacol Date: 2010-12-17 Impact factor: 4.153

Review 6. Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond.

Authors: Paul R Sanberg; Cecilia Vindrola-Padros; R Douglas Shytle
Journal: Physiol Behav Date: 2012-07-06

Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine.

1. Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.

2. Hippocampal α7 nicotinic ACh receptors contribute to modulation of depression-like behaviour in C57BL/6J mice.

Review 3. Neurobiological substrates of Tourette's disorder.

Review 4. Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature.

Review 5. Examining antidepressant drug response by smoking status: why is it important and how often is it done?

Review 6. Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond.

Review 7. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.

8. Neurobehavioral sequelae of traumatic brain injury: evaluation and management.

Review 9. Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

10. Changes in brain MicroRNAs contribute to cholinergic stress reactions.